Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age

Catheterization and Cardiovascular Interventions

Volumn 83, Issue 2, 2014, Pages 182-189

  Ndrepepa, Gjin ^a   Neumann, Franz Josef ^b   Schulz, Stefanie ^a   Fusaro, Massimiliano ^a   Cassese, Salvatore ^a   Byrne, Robert A ^a   Richardt, Gert ^c   Laugwitz, Karl Ludwig ^d,e   Kastrati, Adnan ^a,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^c Herzzentrum der Segeberger Kliniken   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

bleeding; elderly; mortality; myocardial infarction; stenting

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HIRULOG;

AGED; ARTICLE; BLEEDING; BLEEDING ACADEMIC RESEARCH CONSORTIUM; CONTROLLED STUDY; CORONARY STENT; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE; THROMBOSIS; VERY ELDERLY;

BLEEDING; ELDERLY; MORTALITY; MYOCARDIAL INFARCTION; STENTING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTITHROMBINS; CHI-SQUARE DISTRIBUTION; FEMALE; HEMORRHAGE; HIRUDINS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892822405     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25189     Document Type: Article

References (31)

1. Kinsella K,. Urban and rural dimensions of global population aging: An overview. J Rural Health 2001; 17: 314-322.
2. Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: The primary angioplasty in myocardial infarction (pami) trail. J Am Coll Cardiol 1995; 25: 370-377.
3. Wennberg DE, Makenka DJ, Sengupta A, Lucas FL, Vaitkus PT, Quinton H, O'Rourke D, Robb JF, Kellett MA Jr, Shubrooks SJ Jr, Bradley WA, Hearne MJ, Lee PV, O'Connor GT,. Percutaneous transluminal coronary angioplasty in the elderly: Epidemiology, clinical risk factors, and in-hospital outcomes. The northern new england cardiovascular disease study group. Am Heart J 1999; 137: 639-645.
4. Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM,. Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med 2003; 114: 307-315.
5. Sheifer SE, Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Breall JA, Schulman KA,. Time to presentation with acute myocardial infarction in the elderly: Associations with race, sex, and socioeconomic characteristics. Circulation 2000; 102: 1651-1656.
6. Shanmugasundaram M,. Percutaneous coronary intervention in elderly patients is it beneficial? Texas Heart Institute Journal 2011; 38: 398-403.
7. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A, Kastrati A,. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-697.
8. Chhatriwalla AK, Amin AP, Kennedy KF, House JA, Cohen DJ, Rao SV, Messenger JC, Marso SP, National Cardiovascular Data R. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013; 309: 1022-1029.
9. Mehran R, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, Stone GW,. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the replace-2 (randomized evaluation of pci linking angiomax to reduced clinical events), acuity (acute catheterization and urgent intervention triage strategy), and horizons-ami (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011; 4: 654-664.
10. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ,. Predictors of major bleeding in acute coronary syndromes: The global registry of acute coronary events (grace). Eur Heart J 2003; 24: 1815-1823.
11. Rao SV, Dai D, Subherwal S, Weintraub WS, Brindis RS, Messenger JC, Lopes RD, Peterson ED,. Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. JACC Cardiovasc Interv 2012; 5: 958-965.
12. Lopes RD, Subherwal S, Holmes DN, Thomas L, Wang TY, Rao SV, Magnus Ohman E, Roe MT, Peterson ED, Alexander KP,. The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-st-segment elevation myocardial infarction. Eur Heart J 2012; 33: 2044-2053.
13. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A,.; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-238.
14. Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A,; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110: 3627-3635.
15. Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, Glatthor C, Siebert S, Dirschinger J, Schömig A,; ISAR-SMART-2 Investigators. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med 2004; 256: 388-397.
16. Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A,; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295: 1531-1538.
17. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schömig A,; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696. Erratum in: N Engl J Med 2008;359:983.
18. Schulz S, Mehilli J, Neumann FJ, Schuster T, Massberg S, Valina C, Seyfarth M, Pache J, Laugwitz KL, Büttner HJ, Ndrepepa G, Schömig A, Kastrati A,; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3A Trial Investigators. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31: 2482-2491.
19. Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schömig A, Berger PB, Mehilli J,; ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365: 1980-1989.
20. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H,. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation 2011; 123: 2736-2747.
21. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
22. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research C. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
23. Grambsch PM, Therneau TM,. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81: 515-526.
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS,. Evaluating the added predictive ability of a new marker: From area under the roc curve to reclassification and beyond. Stat Med 2008; 27: 157-172; discussion 207-112.
25. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA, Global Registry of Acute Coronary Events I: Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345-2353.
26. Bach RG, Cannon CP, Weintraub WS, DiBattiste PM, Demopoulos LA, Anderson HV, DeLucca PT, Mahoney EM, Murphy SA, Braunwald E,. The effect of routine, early invasive management on outcome for elderly patients with non-st-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141: 186-195.
27. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB III, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR, Investigators S,. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-1017.
28. Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ, Richardt G, Schulz S, Laugwitz KL, Massberg S, Schomig A, Kastrati A,. Validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012; 125: 1424-1431.
29. Bagur R, Bertrand OF, Rodes-Cabau J, Rinfret S, Larose E, Tizon-Marcos H, Gleeton O, Nguyen CM, Roy L, Costerousse O, De Larochelliere R,. Comparison of outcomes in patients ≥ 70 years versus <70 years after transradial coronary stenting with maximal antiplatelet therapy for acute coronary syndrome. Am J Cardiol 2009; 104: 624-629.
30. Vavalle JP, Rao SV,. Impact of bleeding complications on outcomes after percutaneous coronary intervention. Interv Cardiol 2009; 1: 51-62.
31. Romaguera R, Wakabayashi K, Laynez-Carnicero A, Sardi G, Maluenda G, Ben-Dor I, Torguson R, Kent KM, Satler LF, Suddath WO, Lindsay J, Pichard AD, Waksman R,. Association between bleeding severity and long-term mortality in patients experiencing vascular complications after percutaneous coronary intervention. Am J Cardiol 2012; 109: 75-81.